Through the partnership, Elligo’s offerings will be made available to Consortia’s provider network, including its OB-GYN and urology clinics. Elligo will provide various clinical research services, technology, infrastructure, and personnel.
According to Elligo, the partnership leverages its Goes Direct capabilities, which addresses clinical trial patient participation and retention barriers.
“Using electronic health records and other health data, we identify patients for research studies, then provide their physicians with the personnel, processes, technology, and infrastructure necessary to conduct the study in their own clinics,” said John Potthoff, CEO of Elligo.
“We help bring treatment options to patients from physicians they trust, diversifying patient pools and making clinical research study data more realistic,” he told us.
Several clinics have been selected for clinical trials and are enrolling patients, with additional clinics added each week.
“Consortia is working with some of the best women’s health clinics in the country, and, this is a way for Elligo to partner with those same clinics to enable them to offer clinical trials to their patients,” Potthoff added.
Elligo also recently named Rebecca Kush, Ph.D., as scientific innovation officer. Kush is the founder and former president and CEO of the Clinical Data Interchange Standards Consortium (CDISC).